Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Europe Camping Tents Market to Gear Up with $1.5 Billion Revenue by 2029 -…
The Europe Camping Tents Market Report Scope The Europe Camping Tents Market Report Scope Consumers acrossEuropeare progressively gravitating towards camping tent designs, prioritizing lightweight and portability. This inclination underscores a desire for seamless outdoor experiences, where the ease of transportation becomes a paramount consideration. The market responds by offering innovative designs that provide shelter and align with the contemporary demand for hassle-free and...
PR Newswire
24/04/2024
Calliditas Therapeutics' 2023 Annual Report Published
Åsa Hillsten, Head of IR & Sustainability, CalliditasTel.: +46 76 403 35 43, Email:
[email protected]
Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:
[email protected]
This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was sent for publication, through the agency of the contact persons set out above, onApril 24, 2024, at7:00 p.m...
PR Newswire
24/04/2024
Groupe Casino: BUT, Conforama, MDA Company, Casino Group and Intermarché end…
Press release Paris, 24 April 2024BUT, Conforama, MDA Company, Casino Group and Intermarché end their technical goods *purchasing partnership,Sirius AchatsAfter almost two years, BUT, Conforama, MDA Company, Casino Group and Intermarché have decided, in accordance with the terms of their agreements, to terminate their central purchasing hub Sirius Achats with effect from 15 June 2024. Each banner can now forge new partnerships in technical goods purchasing or deepen...
Nasdaq GlobeNewswire
24/04/2024
Estithmar Holding reinforces its expansion in the healthcare sector in Iraq by…
The agreement was signed by Dr. Sabah Noor Al-Musawi, Director General of Karbala Health and Eng. Mohammed bin Bader Al-Sadah, in his capacity as Group CEO of Estithmar Holding. The agreement was signed by Dr. SabahNoor Al-Musawi, Director General of Karbala Health and Eng.Mohammed bin Bader Al-Sadah, in his capacity as Group CEO of Estithmar Holding. On this occasion, Eng.Mohammed bin Bader Al-Sadah, Group CEO of Estithmar Holding, commented on Elegancia Healthcare's expansion in...
PR Newswire
24/04/2024
Virbac : Public release of Virbac Annual Report at 31 December 2023 (ESEF…
Public release of Virbac Annual Report at 31 December 2023 (ESEF format).The Group released and filed its 2023 Annual Report with the French “Autorité des marchés financiers”.The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and pdf format. Attachment Public release of Virbac Annual Report at 31 December 2023 (ESEF format)
Nasdaq GlobeNewswire
24/04/2024
Basilea shareholders approve all proposals of the board of directors at the…
Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today's annual general meeting (AGM) for the financial year 2023.At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for...
Nasdaq GlobeNewswire
24/04/2024
Casino Group: Reverse share split
Casino launches reverse share splitParis, 24 April 2024Casino, Guichard-Perrachon (" Casino") announces today (i) the implementation of the reverse share split of its share capital through the exchange of one hundred (100) existing shares for one (1) new share and (ii) the reduction in share capital by reducing the nominal value of shares decided by the Board of Directors of Casino on 24 April 2024, in accordance with the twelfth and thirteenth resolutions approved by the…
Nasdaq GlobeNewswire
24/04/2024
Casino Group: Q1 2024
FIRST-QUARTER 2024 Consolidated net sales of €2.1bn in Q1 2024 1 Convenience brands: €1.8bn (+0.1% on a same-store basis)Monoprix: €1.1bn (+0.7%)Franprix: €406m (+0.6%)Casino: €349m (-2.4%) Cdiscount:€242m (-21.1%) linked to the planned reduction in direct sales Adjusted EBITDA after lease payments 2of -€10m(vs. €35m in Q1 2023) Free cash flow excluding disposal plan/restructuring costs 3of -€327m in Q1 2024(-€226m in Q1 2023) after payment of...
Nasdaq GlobeNewswire
24/04/2024
CQ Medical™ (formerly CIVCO Radiotherapy and Qfix) is Exhibiting New Brand and…
The company encourages attendees to visit booth #820 to see how two legacy companies are integrating their market-leading solutions, uniquely combining medical technology with patient empathy, to help achieve better patient outcomes. Two special product unveilings will take place on Friday, 3 May at 19:18, which you will want to attend. The company encourages attendees to visit booth #820 to see how two legacy companies are integrating their market-leading solutions, uniquely combining…
PR Newswire
24/04/2024
Vaccines Market Worth $94.9 billion | MarketsandMarkets™
Browse in-depth TOC on "Vaccines Market"394 - Tables57 - Figures414 - Pages Browse in-depth TOC on "Vaccines Market" 394 - Tables 57 - Figures 414 - Pages Vaccines Market Scope: The conjugate vaccine segment is expected to have the dominant share of the vaccine market (excluding COVID-19 vaccines) in 2023. Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines,...
PR Newswire
24/04/2024
Ultimovacs Announces Poster Presentation at the 2024 American Society of…
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II...
Nasdaq GlobeNewswire
24/04/2024
PHARMANUTRA: SUCROSOMIAL® TECHNOLOGY ARRIVES IN UNITED STATES
The Italian company's initial success inthe United States, where it has already obtained numerous patent and scientific recognitions from the medical community over many years, has come as a result of the effectiveness of the proprietary technologies which form the basis of the formulation of the products with which, in just 20 years, it has achieved leadership in the Italian market and significant shares of the foreign markets where it operates through exclusive distributors...
PR Newswire
24/04/2024
Unity Health Toronto partners with Cure51 to identify the biological…
As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project. With a shared commitment to advancing medical innovation and improving patient outcomes, this partnership is poised to drive groundbreaking discoveries in the field of oncology. Cure51 is building the first global clinical and multi omics database of exceptional survivors with over 1100 patients from all continents...
PR Newswire
24/04/2024
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge…
LOS ANGELES and AMSTERDAM, April24, 2024(GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing...
Nasdaq GlobeNewswire
24/04/2024
Novo Nordisk A/S - Articles of Association, April 2024
Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024
Nasdaq GlobeNewswire
24/04/2024
Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 24 April 2024– At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B...
Nasdaq GlobeNewswire
24/04/2024
Lykos Therapeutics Announces Completion of European Phase 2 Study for…
"Given the substantial need for new treatment options for individuals with mental health conditions in Europe, the completion of this Phase 2 study is an important step to helping address unmet needs outside the United States," said Amy Emerson, chief executive officer at Lykos Therapeutics. "By pursuing FDA approval of MDMA-assisted therapy first, we believe the learnings will be beneficial as we determine our regulatory strategy in the United Kingdom and Europe. We are exploring…
PR Newswire
24/04/2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth…
2023 business growth serving patient needs 2023 business growth serving patient needs Chiesi reached over €3 billion in sales – a 10% growth (+12% @CER) on the previous year – maintaining an EBIDTA of approximately 30% for the fourth consecutive year. In 2023, the Company reinforced its strong momentum across geographies and business areas. At constant exchange rates (@CER), growth was observed in all three of the Group's business areas (AIR - respiratory diseases, RARE - rare and...
PR Newswire
24/04/2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680…
Vibrance-1 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in people with NT1. Participants will be randomized to receive one of three doses of ALKS 2680 (4 mg, 6 mg or 8 mg) or placebo to be taken once-daily for six weeks. The primary endpoint will assess whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as measured by the change in…
PR Newswire
24/04/2024
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License…
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021 The antibody program selected for development (now known as NKTR-0165) is designed to modulate the TNFR2 pathway in order to agonize - or activate - T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. Under the 2021...
Nasdaq GlobeNewswire
24/04/2024
Pharma Parenteral Packaging Market in the North America is Anticipated to…
Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Pharma parenteral packaging is created to hold and transport sterile pharmaceutical goods administered through injections. These packaging techniques keep medical products safe, contamination-free, and undamaged in storage, and transit and maintain their potency. The growing pharmaceutical sector, increasing...
PR Newswire
24/04/2024
Esaote Group: Shareholders' Meeting approves financial statements as of 31…
All the main Group consolidated figures for the 2023 financial year are up: net sales revenues at€ 273.2 million( +6.5%on 2022);EBITDA at€ 41.7 million( +24.5%on 2022) ; Group operating income at€ 13.4 million,( +43%on 2022);consolidated net profit at€ 6.2 million,quadrupled compared to 2022 ( € 1.2 million). " The FY2023 results confirmfurther progress of theGroup , which continues to expand, as evidenced by the 7.6% average annual growth we...
PR Newswire
24/04/2024
TVM Capital Healthcare Announces US$ 17 Million Investment into neurocare
neurocare, through its digital therapy platform (DTP), provides a holistic and patient centric treatment for a variety of psychological or neurological conditions. It uses innovative mental health care methods and tools including sleep assessment, therapeutics, psychotherapy, TMS and neurofeedback, all supervised within a cloud-based solution, to empower clinicians and deliver individualized care. Following a detailed assessment of the patient's condition, neurocare supports clinicians in…
PR Newswire
24/04/2024
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05…
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Nasdaq GlobeNewswire
24/04/2024
Altri Comunicati